Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

 Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

Shots:

  • Sangamo provides an update on its pre/ clinical pipeline and emphasizes on its global capabilities across clinical science, operations, product development and manufacturing at its R&D day
  • The company highlights the completion of IND transfer to Pfizer for its gene therapy candidate, SB-525 with the expected onset of its P-III study in 2020 by Pfizer. Sangamo also provides an overview of its engineered ex vivo cell therapies for beta-thalassemia, kidney transplantation and preclinical candidates for MS
  • The company is targeting new gene therapy and genome regulation programs for clinical development with their expected IND submission in 2021 and 2022 for Alzheimer’s and Parkinson’s disease. It also reveals its CAR-TREG clinical and preclinical programs

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Sangamo

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post